Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 24:14:1759720X221100299.
doi: 10.1177/1759720X221100299. eCollection 2022.

A glance into the future of myositis therapy

Ilaria Chiapparoli  1 , Claudio Galluzzo  1 , Carlo Salvarani  1 , Nicolò Pipitone  2
Affiliations
Review

A glance into the future of myositis therapy

Ilaria Chiapparoli et al. Ther Adv Musculoskelet Dis. .

Abstract

The idiopathic inflammatory myopathies are chronic diseases of the skeletal muscle that comprise various conditions, including dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and the antisynthetase syndrome. Although there are a number of distinguishing features, all these disorders are characterized by an immune and inflammatory response mainly directed against the muscle. Hence, therapy is geared toward curbing the autoimmune and inflammatory response. A quite wide range of medications are currently available to treat these disorders, but despite all therapeutic progress still a number of patients are unable to maintain a sustained remission. In this review article, we have marshaled a variety of potential therapeutic agents that may hold promise for the future treatment of the idiopathic inflammatory myopathies. It is to be expected that by increasing the therapeutic armamentarium with agents that have different mechanisms of action even challenging cases could be successfully managed, thus reducing disease burden and disability.

Keywords: dermatomyositis; glucocorticoids; immunosuppressants; myositis; polymyositis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: IC: none. CG: none. CS: received consulting and investigator fees from Abbvie, Pfizer, MSD, Roche, Celgene, and Novartis. NP: Guest speaker at UCB-sponsored meetings: (Immunology Summits, Prague, 2012, 2013, & 2014, MACRO Meet the expert at the ACademy of RheumatOlogy, Bologna 13–14 April 2012, GRAPPA Workshop, Milan 29 January 2016 and Rome 30 November 2017), Fininvest (Catania 2016), Aim Group (Reggio Emilia 2018), I&C (Bologna, 2018), Alfa-Wassermann/Planning congressi sponsored meeting (Rhewind, Bologna, February 2016 and 2019). Received royalties from Uptodate.com and consultant fees from Janssen-Cilagin. Investigator in the CL2-78989-010 Servier study (2014) and the sirukumab in GCA GSK study (2016); PI for the ToReMy (Tocilizumab in Refractory Myositis) AIFA [Italian Drug Agency]-funded (2017) study and for the FOREUM-funded (2018) GCA study; investigator for the ADIENNE ADN016 study (2022).

References

    1. Pipitone N, Salvarani C. Treatment of inflammatory myopathies. Expert Rev Clin Immunol 2018; 14: 607–621. - PubMed
    1. Smith LN, Paik JJ. Promising and upcoming treatments in myositis. Curr Rheumatol Rep 2020; 22: 65. - PMC - PubMed
    1. Allenbach Y, Guiguet M, Rigolet A, et al.. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS ONE 2015; 10: e0133702. - PMC - PubMed
    1. Oddis CV, Reed AM, Aggarwal R, et al.. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314–324. - PMC - PubMed
    1. Fasano S, Gordon P, Hajji R, et al.. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford) 2017; 56: 26–36. - PubMed

LinkOut - more resources